Characterizing Virological Suppression in Today's Treatment Paradigm

Key Objectives of This Program

Virological Suppression Represents Success for the Patient

Definitions of Virological Suppression

What Constitutes Virological Failure?

How Can We Limit Virological Failure?

How Do We Define Success With Highly Efficacious Treatment?

Defining Success in Treatment-Naive Patients

GEMINI-1 and -2 Phase 3 Study Designs

GEMINI-1 and -2 Phase 3 Primary Outcomes

GEMINI-1 and -2: Analysis of Participants With TND Over Baseline VL for 2DR and 3DR

Considerations for Clinicians

FLAIR: Long-Acting Cabotegravir + Rilpivirine for HIV Maintenance

FLAIR: Results for Primary and Secondary Endpoints

FLAIR: Injection Site Reactions

FLAIR: Patient Preference Survey

FLAIR: Patients Who Experienced Virologic Failure CAB LA + RPV LA Arm

Clinical Case: 48-Year-Old Man

Clinical Case: 48-Year-Old Man (cont)

Clinical Case: 48-Year-Old Man (cont)

Considerations for Clinicians (cont)

Clinical Case: 46-Year-Old Woman

Clinical Case: 46-Year-Old Woman (cont)

SWORD-1 and -2: Analysis of Viral Replication for 2DR vs 3DR

Clinical Case: 46-Year-Old Woman (cont)

PARTNER Study

PARTNER: Key Conclusions

Communicating With Patients Regarding Virological Suppression

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)